Abstracts tagged "Biologicals"

Abstract Number: 2438 • ACR Convergence 2024
Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus
Vasileios Kyttaris¹, Gelareh Atefi², Dan Persons³, Dana Withrow³ and Mawuena Binka⁴, ¹BIDMC, Boston, MA, ²AstraZeneca, Media, PA, ³Trio Health, Louisville, CO, USA, Louisville, ⁴BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE
Background/Purpose: Oral corticosteroids (OCS) are a mainstay in the clinical management of systemic lupus erythematosus (SLE). However, prolonged use may result in systemic side effects.1…
Abstract Number: 2653 • ACR Convergence 2024
Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis
Elaine Yung¹, Xiaoxuan Liu², Bin Huang³, Michael Wagner¹, Minal Aundhia², Chen Chen⁴ and hermine brunner⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cin, OH, ⁵Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: When uncontrolled, JIA is associated with short-term and long-term complications that affect the patient’s quality of life. A common goal of treatment is to…
Abstract Number: 0384 • ACR Convergence 2024
Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study
Corey J. Bishop¹, Edwin Lam², Sophia G. Liva³, Jocelyn H. Leu², Amy S. Paller⁴, Lucia Z. Diaz⁵, Laura Wine Lee⁶, Cory Rubin⁷, Ruy Carrasco⁸, Lisa Imundo⁹, Azadeh Majlessi¹⁰, Katherine Berezny¹, Kathleen G. Lomax¹, Valerie Smith¹, Renping Zhang¹ and hermine brunner¹¹, ¹Janssen Research & Development, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, ³Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁴Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁵Dell Children’s Medical Center; Dell Medical School at the University of Texas at Austin, Austin, TX, ⁶Medical University of South Carolina, Charleston, SC, ⁷Michigan Dermatology Institute, Waterford, MI, ⁸Pediatric Rheumatology Consultants of Austin, Austin, TX, ⁹Columbia University Medical Center, New York, NY, ¹⁰Newport Huntington Medical Group, Huntington Beach, CA, ¹¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study…
Abstract Number: 0507 • ACR Convergence 2024
Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib
Runa Kuley¹, Bhargavi Duvvuri¹, Sabeeha Hasnain², Ernst Dow³, Alisa Koch⁴, Richard Higgs⁴, Venkatesh Krishnan⁴ and Christian Lood⁵, ¹University of Washington, Seattle, ²Mahindra University, Hyderabad, India, ³Eli Lilly and Co, Indianapolis, IN, ⁴Eli Lilly, Indianapolis, IN, ⁵University of Washington, Seattle, WA
Background/Purpose: Neutrophils play an important role in regulating immune and inflammatory responses in rheumatoid arthritis (RA). We assessed whether baricitinib, a JAK1/JAK2 inhibitor, could reduce…
Abstract Number: 0589 • ACR Convergence 2024
Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials
Laura Coates¹, Iain McInnes², M. Elaine Husni³, Cynthia Vizcaya⁴, Weibin Bao⁵ and Philip Mease⁶, ¹University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, ²University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ³Cleveland Clinic, Cleveland, OH, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory disease that can manifest with considerable clinical heterogeneity. Secukinumab demonstrated improvements across the updated Group for Research and…
Abstract Number: 0825 • ACR Convergence 2024
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): 6-month Outcomes of a Longitudinal Cohort Study
Arielle Mendel¹, Lillian Barra², Sasha Bernatsky³, Alison Clifford⁴, Mojtaba Dabaghjamanesh⁵, Natasha Dehghan⁶, Aurore Fifi-Mah⁷, Jean-Paul Makhzoum⁸, Rosalie-Sélène Meunier⁹, Nataliya Milman¹⁰, Medha Soowamber¹¹, Jan Willem Cohen Tervaert¹², Elaine Yacyshyn⁴, Nader Khalidi¹³ and Christian Pagnoux¹⁴, ¹McGill University Health Centre, Montreal, QC, Canada, ²Western University, London, ON, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Western University, Canada, Richmond Hill, ON, Canada, ⁶University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁹Hôpital Sacré-Coeur, Université de Montréal, Montreal, QC, Canada, ¹⁰the Ottawa Hospital, Ottawa, ON, Canada, ¹¹Mount Sinai Hospital, Woodbridge, ON, Canada, ¹²University of Alberta, Edmonton, Canada, ¹³McMaster University, Hamilton, ON, Canada, ¹⁴Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: To evaluate the effectiveness and safety of rituximab (RTX) biosimilars compared to the originator in Canadians with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis…
Abstract Number: 1106 • ACR Convergence 2024
Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients
Adrián Martín-Gutiérrez¹, Javier Loricera², Carmen Secada Gómez³, Clara Moriano⁴, Javier Narvaez-García⁵, Vicente Aldasoro⁶, Olga Maíz Alonso⁷, Iñigo Hernández-Rodríguez⁸, Paloma Vela-Casasempere⁹, Susana Romero Yuste¹⁰, Eugenio De Miguel¹¹, Eva Galindez-Agirregoikoa¹², Jesus C. Fernandez-López¹³, ivan Ferraz-Amaro¹⁴, Julio Sánchez-Martín¹⁵, José Luis Callejas¹⁶, Patricia Moya Albarado¹⁷, Cristina Campos Fernández¹⁸, Fernando Lopez-Gutierrez¹⁹, Santos Castañeda²⁰ and Ricardo Blanco-Alonso²¹, and the Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital León, LEON, Spain, ⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Hospital Universitario de Navarra, Pamplona, Spain, ⁷3Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, ⁸Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁹Hospital General Universitario Alicante, Alicante, Spain, ¹⁰Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, ¹¹Hospital Universitario La Paz, Madrid, Spain, ¹²BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹³11Rheumatology, Hospital Universitario Juan Canalejo, A Coruña, Spain., A Coruña, Spain, ¹⁴Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ¹⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁶Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ¹⁷Hospital de San Pau, Barcelona, Spain, ¹⁸Escuela de Doctorado, Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain, ¹⁹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²⁰Hospital Universitario de la Princesa, Madrid, Spain, ²¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Tocilizumab (TCZ) is the only biological drug approved for the treatment of giant cell arteritis (GCA). Clinical trials were performed with intravenous (IV) and…
Abstract Number: 1454 • ACR Convergence 2024
Treatment Patterns, Clinical Characteristics, and Patient-Reported Outcomes Among Patients with Axial Spondyloarthritis Treated in Real-World Rheumatology Practices in the US
Andrew Concoff¹, Riley Taiji², Linda Grennell-Merrick³, Jonathan Rodrigues³, Courtney McDermot⁴, Usha Madhukar Niak³, Raluca Ionescuittu⁵, Ariane Faucher², Francis Vekeman² and Tim Nguyen³, ¹United Rheumatology, a Specialty Networks Company, Cleveland, OH, ²StatLog Econometrics, Montreal, QC, Canada, ³Novartis, East Hanover, NJ, ⁴Novartis, Dublin, Ireland, ⁵StatLog Economitrics, Montreal, QC, Canada
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic immune-mediated rheumatic disease with high comorbidity burden. Biologic disease-modifying anti-rheumatic drugs (bDMARDs) and patient-reported outcomes (PROs) are increasingly…
Abstract Number: 1544 • ACR Convergence 2024
Comparison of Efficacy and Safety Between Belimumab and Telitacicept in the Treatment of Systemic Lupus Erythematosus
wanling wei, ling lei, Cheng Zhao, hanyou mo, zhanrui chen, leting zheng, jing wen, Fang Qin, xiaoling liao, wen zeng and fei dong, The First Affiliated Hospital of Guangxi Medical University, nanning, China (People's Republic)
Background/Purpose: B cells play an important role in the pathogenesis of systemic lupus erythematosus(SLE).Multiple biological agents with B lymphocyte as the therapeutic target have recently emerged…
Abstract Number: 1988 • ACR Convergence 2024
A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
Marta Cossu¹, Carolina Bobadilla Mendez², Amanda Jackson³, Eugene Myshkin⁴, Grace Liu⁵, Edwin Lam⁶, Ulf H. Beier², Kathleen Weisel², Brittney Scott², Jocelyn H. Leu⁶, Sheng Gao² and Dessislava Dimitrova², ¹Janssen Pharmaceutical Research and Development, a Johnson & Johnson company, Leiden, Netherlands, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, ³Janssen Research & Development, LLC, La Jolla, CA, ⁴Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, ⁵Janssen Research & Development, LLC, a Johnson & Johnson company, Raritan, NJ, ⁶Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA
Background/Purpose: Nipocalimab is a human IgG1 monoclonal antibody targeting the neonatal Fc receptor (FcRn) that selectively reduces IgG levels without impacting antigen presentation, T- and…
Abstract Number: 2257 • ACR Convergence 2024
Comparison of the Safety and Effectiveness of Originator Rituximab (Mabthera®) versus Biosimilar (Riximyo®) in Rheumatoid Arthritis: A Retrospective Unicentric Analysis
Barbara Bayeh¹, Fanny Neira¹, Karina Bonfiglioli¹, Nadia Aikawa², ANA PAULA ASSAD¹, Renata Miossi¹, Fernando Souza³, Carlos Emilio Insfran Echauri¹, Henrique Giardini¹, Emily Figueiredo Neves Yuki¹, Henrique Carriço Da Silva¹, Andre Franco¹, Diogo Domiciano¹, Julio Moraes⁴, Eloisa Bonfa¹, Carla Goncalves Schahin Saad³, Ana Cristina Medeiros-Ribeiro⁵ and Andrea Shimabuco³, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil
Background/Purpose: Immunobiological drugs emerged as a revolutionary option for treating inflammatory chronic rheumatic diseases, particularly rheumatoid arthritis (RA). However, the extremely high costs associated with…
Abstract Number: 2440 • ACR Convergence 2024
Ambispective, Multicenter Registry of Treatment with Anifrolumab in Real Life in Patients with Systemic Lupus Erythematosus from Spanish Rheumatology Departments (ANIFRO-Reu): Efficacy, Safety and Patient’s Characteristics
Irene Carrión-Barberà¹, Tarek Carlos Salman Monte:², Laura Triginer³, María García-Villanueva⁴, Sandra Garrote Corral⁵, Anne Riveros Frutos⁶, Judit Font⁷, María Galindo-Izquierdo⁸, Carlos de Frías Polo⁹, Jorge Juan Fragío Gil¹⁰, Clara Moriano¹¹, Elvira Díez Álvarez¹², Pilar Bernabéu¹³, Paloma Vela-Casasempere¹⁴, Josefina Cortés-Hernández¹⁵, Sebastián Sandoval Moreno¹⁶, Javier Narvaez-García¹⁷, Andrea Hernández-Martín¹⁸, Berta Paula Magallares¹⁹, María Piqueras García²⁰, Carlos Marras²¹, Consuelo Ramos²², Jose Alfredo Gomez-Puerta²³, Beatriz Frade-Sosa²⁴, Ana Fernández-Ortiz²⁵, Angel Garcia-Aparicio²⁶, Irene Altabás-González²⁷, Samuel Hernández-Baldizón²⁸, Inmaculada Ros-Vilamajó²⁹, Silvia García Cirera³⁰, Marta Garijo Bufort³¹, Luis Sala³², Julia Martínez-Barrio³³, José Rosas-Gómez de Salazar³⁴, Sergi Heredia³⁵, Vicenç Torrente-Segarra³⁶, Anahy Maria Brandy-Garcia³⁷, Natividad del Val del amo³⁸, Concepción Fito-Manteca³⁸, Jaime Calvo-Alen³⁹, José María Pego-Reigosa⁴⁰ and Íñigo Rúa-Figueroa⁴¹, ¹Hospital del Mar, Barcelona, Spain, ²Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ³Hospital del Mar Research Institute, Barcelona, Spain, ⁴Hospital Ramón y Cajal, MADRID, Madrid, Spain, ⁵Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁶Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁷Hospital Germans Trias i Pujol, Barcelona, Spain, ⁸Hospital 12 de Octubre, Madrid, Madrid, Spain, ⁹Hospital 12 de Octubre, Madrid, Spain, ¹⁰Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ¹¹Hospital León, LEON, Spain, ¹²Complejo Asistencial Universitario de León, León, Spain, ¹³Rheumatology section, Dr. Balmis General University Hospital-ISABIAL, Alicante, Spain, Alicante, Spain, ¹⁴Hospital General Universitario Alicante, Alicante, Spain, ¹⁵Hospital Universitario Vall d´Hebrón Hospitals, Barcelona, ES, Barcelona, Spain, ¹⁶Hospital Vall d'Hebron, Barcelona, Spain, ¹⁷Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁸Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas, Spain, ¹⁹Dept of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, ES, Barcelona, Spain, ²⁰Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²¹Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ²²Hospital Universitario Virgen de Valme, Sevilla, Spain, ²³Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ²⁴Hospital Clínic, Barcelona, Spain, ²⁵Hospital Universitario de Badajoz, Badajoz, Spain, ²⁶Hospital Universitario de Toledo, Toledo, Spain, ²⁷Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, ²⁸Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ²⁹Hospital Universitari Son Llàtzer, Palma de Mallorca, Islas Baleares, Spain, ³⁰Hospital Parc Taulí, Sabadell, Spain, ³¹Hospital de Sagunto, Sagunto, Spain, ³²Hospital Universitario de Torrejón, Torrejón, Spain, ³³Hospital Gregorio Marañón, Madrid, Spain, ³⁴Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ³⁵Hospital Moisès Broggi, Sant Joan Despí, Spain, ³⁶Hospital Comarcal Alt Penedès-Garraf, Vilafranca, Spain, ³⁷Hospital Germans Trias i Pujol, Badalona, Spain, ³⁸Complejo Universitario de Navarra, Navarra, Spain, ³⁹Hospital Universitario de Araba, Araba, Spain, ⁴⁰Galicia Health Service (SERGAS), Vigo, Spain, ⁴¹Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain
Background/Purpose: Anifrolumab is a biological treatment with recent approval for systemic lupus erythematosus (SLE), supported by its efficacy in clinical trials. However, data from real…
Abstract Number: 0001 • ACR Convergence 2024
Type I Interferon and Anifrolumab Effects on Bone Marrow and Blood Plasma Cells in Systemic Lupus Erythematosus
Diana Alzamareh¹, Nida Pellett², Daria Krenitsky², Wesley Durrett¹, Javier Rangel-Moreno¹, Jennifer Anolik² and Jennifer Barnas¹, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of pathogenic anti-nuclear antibodies (ANA) by plasma cells (PC). Importantly, long-lived plasma…
Abstract Number: 0390 • ACR Convergence 2024
Treatment Effectiveness Following Switching from Initial TNF Inhibitor in Juvenile Idiopathic Arthritis
Mei-Sing Ong¹, Sarah Ringold², Melissa Mannion³, Marc Natter⁴ and Yukiko Kimura⁵, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ²Washington University, Seattle, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston Children's Hospital, Boston, MA, ⁵Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Although the increasing availability of biologic therapies has significantly improved outcomes for patients with JIA, a substantial proportion of patients require switching from the…
Abstract Number: 0512 • ACR Convergence 2024
Co-stimulatory Blockade Causes Targeted Quantitative and Clonotypic Contractions in Extrafollicular B-cell Subsets in Seropositive RA Patients
Jasmine Shwetar¹, William Rigby², Sladjana Skopelia-Gardner³, Abhimanyu Armarnani¹, Kelly Ruggles¹ and Gregg Silverman¹, ¹NYU Grossman School of Medicine, New York, NY, ²Dartmouth-Hitchcock, Norwich, VT, ³Dartmouth Hitchcock Medical Center, Hanover, NH
Background/Purpose: Of all approved biologic therapies, other than anti-CD20 depletion only CTLA4-Ig/abatacept treatment reduces levels of pathologic autoantibodies. Herein, our primary goal has been to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].